Skip to content
Disclosery

Athyrium Capital Management, LP

Follow

13F filer, CIK 1728001, New York, NY

Athyrium Capital Management, LP reported $68,826,290 across 3 holdings for the quarter ended 2023-12-31, in a 13F-HR filed 2024-02-14.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001123292-24-000048

Period
2023-12-31
Reported value
$68.8M
Holdings
3
Top 10 weight
100%
New
0
Sold out
3

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
RVLPQexited-14,600,444-$1.26M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2023

Share positions as resolved from 13F-HR 0001123292-24-000048, largest first. % of portfolio is the value over $68,826,290, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: not reported; 2023Q1: 1,694,481 shares; 2023Q2: 1,694,481 shares; 2023Q3: 10,929,762 shares; 2023Q4: 10,929,762 shares 10,929,762$14.8M21.44%0
PBYIPUMA BIOTECHNOLOGY INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2022Q1: restricted; 2022Q2: restricted; 2022Q3: restricted; 2022Q4: 1,792,114 shares; 2023Q1: 1,792,114 shares; 2023Q2: 1,792,114 shares; 2023Q3: 1,792,114 shares; 2023Q4: 1,792,114 shares 1,792,114$7.76M11.27%0Timeline

Principal amounts

Notes and convertibles filed as a face amount (PRN). A face amount is never added to a share count (H6).

SecurityTypeAmountValueChange
OMEROS CORPOMEROS CORP NOTE 5.250% 2/1principal72,979,000$46.3M0

Sold out in Q4 2023

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
BIORA THERAPEUTICS INCBIORA THERAPEUTICS INC53,500,000$28Mprincipal
Omeros CorpOmeros Corp11,005,000$11.3Mprincipal
RVLPQRVL PHARMACEUTICALS PLC ORDINA14,600,444$1.26Mshares

How Q4 2023 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001123292-24-000048 base2024-02-14acceptance time not in the bulk data set